Literature DB >> 16334166

Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence.

Yen-Kung Chen1, Dar-Shih Hsieh, Chao-Sheng Liao, Chyi-Huey Bai, Chen-Tau Su, Yeh-You Shen, Jih-Fang Hsieh, Alfred C Liao, Chia-Hung Kao.   

Abstract

UNLABELLED: The aim of this study was to evaluate the potential role of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in patients with unexplained rising serum alpha-fetoprotein (AFP) levels after the treatment of hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Thirty-one FDG-PET studies were performed in 26 patients (age range, 45-83; 21 men and 5 women), who had undergone either surgical resection or interventional therapy for HCC, but were subsequently noted to have high AFP serum levels on routine follow-up examinations, although imaging studies and physical examinations were normal. The FDG-PET results were correlated with histological findings, as well as long-term radiological and clinical follow-up (shortest follow-up period after FDG-PET was 6 months).
RESULTS: FDG-PET was abnormal in 22 of the 31 studies (71.0%) among the 26 patients. Intrahepatic lesions were detected in 20 of a total 30 lesions (66.7%) in 18 studies of FDG-PET among 26 patients. Ten FDG-PET studies among 9 patients identified one intrahepatic lesion, while 3 studies among 3 patients identified more than one intrahepatic lesion. Extrahepatic metastases were found in 9/31 studies of FDG-PET (29.0%) among 8 patients. These metastatic foci, composed of increased FDG accumulation, were identified in several locations; lung (4 studies among 4 patients), bone (2 studies among 2 patients) and the peritoneum (4 studies among 3 patients). Overall, FDG-PET for detecting HCC recurrence demonstrated 22 true-positives, 8 false-negatives, 1 true-negative and 0 false-positive results., The sensitivity, specificity and accuracy of FDG-PET for detecting HCC recurrence was 73.3%, 100% and 74.2%, respectively.
CONCLUSION: When conventional examinations are normal, FDG-PET is a valuable imaging tool in patients who have rising AFP levels after HCC treatment. FDG-PET whole-body scan also provides an important and valuable imaging study for detecting extrahepatic metastasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16334166

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  15 in total

1.  Clinical utility and limitations of FDG PET in detecting recurrent hepatocellular carcinoma in postoperative patients.

Authors:  Nobuyuki Hayakawa; Yuji Nakamoto; Koya Nakatani; Etsuro Hatano; Satoru Seo; Tatsuya Higashi; Tsuneo Saga; Shinji Uemoto; Kaori Togashi
Journal:  Int J Clin Oncol       Date:  2013-12-25       Impact factor: 3.402

2.  Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma.

Authors:  Rania Refaat; Mohammad Abd Alkhalik Basha; Mohammed Sobhi Hassan; Rasha S Hussein; Ahmed A El Sammak; Dena Abd El Aziz El Sammak; Mohamed Hesham Saleh Radwan; Nahla M Awad; Somaia A Saad El-Din; Engi Elkholy; Dina R D Ibrahim; Shereen A Saleh; Iman F Montasser; Hany Said
Journal:  Eur Radiol       Date:  2018-06-12       Impact factor: 5.315

Review 3.  Advanced imaging techniques in the therapeutic response of transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Ke Yang; Xiao-Ming Zhang; Lin Yang; Hao Xu; Juan Peng
Journal:  World J Gastroenterol       Date:  2016-05-28       Impact factor: 5.742

4.  Metabolic restaging of hepatocellular carcinoma using whole-body F-FDG PET/CT.

Authors:  Long Sun; Yong-Song Guan; Wei-Min Pan; Zuo-Ming Luo; Ji-Hong Wei; Long Zhao; Hua Wu
Journal:  World J Hepatol       Date:  2009-10-31

5.  Positron emission tomography scan for a hepatic mass.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2010-12       Impact factor: 17.425

Review 6.  Role of positron emission tomography/computed tomography in living donor liver transplantation for hepatocellular carcinoma.

Authors:  Seung Duk Lee; Seong Hoon Kim
Journal:  Hepatobiliary Surg Nutr       Date:  2016-10       Impact factor: 7.293

7.  Hepatocellular carcinoma: management of an increasingly common problem.

Authors:  Gary L Davis; Jane Dempster; James D Meler; Douglas W Orr; Mark W Walberg; Brian Brown; Brian D Berger; John K O'Connor; Robert M Goldstein
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-07

Review 8.  Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies.

Authors:  Long Sun; Hua Wu; Yong-Song Guan
Journal:  World J Gastroenterol       Date:  2007-05-28       Impact factor: 5.742

9.  Early finding of chest wall metastasis of hepatocellular carcinoma in a woman by fluorodeoxyglucose-positron emission tomography scan: a case report.

Authors:  Lixin Yang; Howard Marx; Yun Yen
Journal:  J Med Case Rep       Date:  2011-04-13

10.  FDG-Avid Portal Vein Tumor Thrombosis from Hepatocellular Carcinoma in Contrast-Enhanced FDG PET/CT.

Authors:  Xuan Canh Nguyen; Dinh Song Huy Nguyen; Van Tan Ngo; Simone Maurea
Journal:  Asia Ocean J Nucl Med Biol       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.